Endo And BioDelivery Sciences Update On BEMA Buprenorphine Phase III Trials

(RTTNews) - Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (ENDP), and BioDelivery Sciences International Inc. (BDSI) announced Wednesday that they have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine.

According to the companies, the interim analyses were conducted as part of the Phase III protocol to allow for adjustments to the sample size in order to maintain appropriate study power to detect statistically significant differences between BEMA Buprenorphine and placebo. The analyses were conducted by an independent biostatistician.

Endo and BDSI viewed the outcomes of the interim analyses as encouraging. As a result of the interim analyses, it was determined that no sample size adjustment will be necessary to the opioid naive study. Additional patients will be added to the ongoing opioid experienced trial to maintain appropriate power to allow for the detection of a statistically significant difference between BEMA Buprenorphine and placebo based on the primary efficacy endpoint, the companies said.

"Data from the opioid naive study appear consistent with our original assumptions and no additional patients are required. This study has completed patient enrollment, and we continue to anticipate the study results early next year. We expect that the additional patients required for the opioid experienced trial will result in a slight adjustment to the timing for the completion of that study to mid 2014. While no major impact is anticipated for the timing of the NDA submission, which was scheduled for the second half of 2014, more definitive timing will be provided when patient enrollment is completed,." said Mark Sirgo, President and CEO of BDSI.